11 Apr

Incyte Has Diversified Its Revenues across Multiple Product Lines

WRITTEN BY Margaret Patrick FEATURED IN Company News, Insights, & Analysis

Iclusig trends

Incyte (INCY) expects to report GAAP (generally accepted accounting principles) and non-GAAP revenues in the range of $80 million to $85 million from the sale of Iclusig in fiscal 2018. In June 2016, Incyte entered a licensing agreement with Ariad Pharmaceuticals for the development and commercialization of kinase inhibitor, Iclusig, in the European Union and 22 other countries. Ariad Pharmaceuticals sold all of its European operations to Incyte in June 2016. 

Iclusig is approved in Europe as a treatment option for adults suffering from either chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (or CML), are resistant or intolerant to treatment with Bristol-Myers Squibb’s (BMY) Sprycel (dasatinib) and Novartis’s (NVS) Tasigna (nilotinib), who are not clinically eligible for treatment with Novartis’s Gleevec (imatinib), or who have the T315I mutation. Additionally, Iclusig is also approved for adults suffering from Philadelphia-chromosome positive acute lymphoblastic leukemia (or Ph+ ALL) and who are intolerant or resistant to Sprycel (dasatinib), not clinically eligible for treatment with Gleevec, or have a T315I mutation.

Incyte Has Diversified Its Revenues across Multiple Product LinesRoyalties for Jakavi

In November 2009, Incyte entered a collaboration with Novartis and out-licensed the development and commercialization rights for Jakafi in all hematology and oncology indications in international markets in exchange for milestone payments and royalties. Incyte, however, has retained rights related to the topical formulation of Jakafi. Jakafi is marketed under the brand name of Jakavi by Novartis.

In April 2016, Incyte acquired rights from Eli Lilly (LLY) to develop and commercialize Jakafi in graft versus host disease (or GVHD). The company has also amended its agreement and granted exclusive development and commercialization rights to Novartis related to Jakavi in GVHD indication in international markets.

Check out all the data we have added to our quote pages. Now you can get a valuation snapshot, earnings and revenue estimates, and historical data as well as dividend info. Take a look!

In the next article, we’ll discuss growth prospects for Olumiant in greater detail.

Latest articles

Verizon Communications stock (VZ) closed down 2.09% on Tuesday after the leading US mobile carrier reported mixed results for the first quarter of 2019 before the market bell yesterday.

24 Apr

Nokia’s Patent Business Is Put On the Spot

WRITTEN BY Rachel Gunter

Several European auto companies want Nokia’s (NOK) patent business subjected to an antitrust probe.

The first-quarter semiconductor earnings season has begun, and the stock market is showing bullish sentiment as investors buy ahead of earnings releases.

Netflix (NFLX) is working its way through a series of price increases in several markets, including the United States and parts of Europe.

Netflix (NFLX) is aiming to add 14.6 million paying subscribers in the first six months of 2019.

Earlier today, the second-largest US automaker, Ford Motor Company (F), announced a plan to invest $500 million in Plymouth-based automotive company Rivian.